Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EZH2 in Acral Lentiginous Melanoma: Molecular, Epigenetic, and Therapeutic Perspectives.

Oncology research - 1 Jan 2026

de Oliveira Daniel Arcuschin, Nisimoto Melissa Yoshimi Sakamoto Maeda, Hunnicutt Jaciara Moreira Sodré, Sartori Eduarda Massa, Marques Amanda Fáris, Paschoal Francisco Macedo, Marti Luciana Cavalheiro, Jasiulionis Miriam Galvonas, Neto Miguel Sabino, Filho Renato Santos de Oliveira

Abstract excerpt

Acral lentiginous melanoma (ALM) is characterized by a low mutational burden, frequent chromosomal rearrangements, and profound epigenetic dysregulation, distinguishing it from ultraviolet (UV)-induced melanoma. Among the epigenetic regulators, Enhancer of Zeste Homolog 2 (EZH2), the catalytic component of the Polycomb Repressive Complex 2 (PRC2), plays a central role in chromatin compaction and transcriptional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enhancer of Zeste Homolog 2 Protein
Share to Epigenesis, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to NRAS gene

Share to Melanoma

Share to Molecular Targeted Therapy

Share to Mutation

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42220432
DOI: 10.32604/or.2026.077913
PMCID: PMC13220097

Genes

BRAF
NRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZH2 in Acral Lentiginous Melanoma: Molecular, Epigenetic, and Therapeutic Perspectives.PMID 42220432Read ↗

The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.Semantic proximity Read ↗

The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor ImmunotherapySemantic proximity Read ↗

Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.Semantic proximity Read ↗

Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted TherapiesSemantic proximity Read ↗

Epigenetics and Cutaneous Neoplasms: From Mechanism to TherapySemantic proximity Read ↗

Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy.Semantic proximity Read ↗

Role of Epigenetics in Uveal MelanomaSemantic proximity Read ↗

Stat3 co-operates with mutant <i>Ezh2</i> <sup>Y641F</sup> to regulate gene expression and limit the anti-tumor immune response in melanomaSemantic proximity Read ↗

HDAC Inhibition Increases HLA Class I Expression in Uveal MelanomaSemantic proximity Read ↗

Role of Histone Deacetylases in Drug-Resistant Melanoma: Mechanisms and Therapeutic ImplicationsSemantic proximity Read ↗

Ezh2Y641F mutations co-operate with Stat3 to regulate MHC class I antigen processing and alter the tumor immune response in melanoma.Semantic proximity Read ↗

Mi-2β promotes immune evasion in melanoma by activating EZH2 methylationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.